Core Viewpoint - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center, focusing on innovative treatment solutions for brain tumor patients [1][2]. Group 1: Strategic Cooperation - The cooperation aims to build a high-level radiotherapy platform centered on specialized treatment for brain tumors, utilizing the ZAP-X radiotherapy robot [1][2]. - The partnership is seen as a new starting point for both parties, with aspirations to enhance diagnostic and treatment capabilities in the field of oncology, particularly for brain tumors [2]. Group 2: Technology and Innovation - The ZAP-X technology is described as revolutionary in the field of cranial radiotherapy, significantly improving the precision and safety of brain tumor treatments [2]. - ZAP-X employs a unique dual-rotating spherical structure, allowing X-rays to target tumors from thousands of non-coplanar angles, effectively destroying tumors while protecting surrounding healthy brain tissue [2]. - The device has achieved approvals in 24 countries and regions globally, with over 5,000 clinical treatments completed [2]. Group 3: Company Development - Baiyang Pharmaceutical is advancing its transformation into a technology-driven enterprise, focusing on optimizing medical scenarios through technological innovation [3]. - The company has established a comprehensive industrial chain in the radiotherapy field, covering research and development, production, and operation [3]. - Baiyang aims to continue building precision radiotherapy centers and applying advanced radiotherapy equipment in clinical settings to benefit more patients in China [3].

Core Viewpoint - The strategic partnership between Baiyang Pharmaceutical and Peking University International Hospital aims to establish a precision radiotherapy center focused on brain tumor treatment, utilizing the ZAP-X robotic system to enhance treatment efficacy and safety for patients [1][2] Group 1: Partnership and Collaboration - Baiyang Pharmaceutical signed a strategic cooperation agreement with Peking University International Hospital to jointly build a precision radiotherapy center [1] - The center will leverage the ZAP-X robotic system, which is recognized as a revolutionary technology in cranial radiotherapy, to improve the precision and safety of brain tumor treatments [1] Group 2: Market Context and Technology - Brain tumors present a global treatment challenge, with traditional surgical methods often leading to secondary injuries such as nerve damage or cerebral edema [1] - The ZAP-X system has been approved for use in 24 countries and regions worldwide, having completed over 5,000 clinical treatments, showcasing its effectiveness in the field [1] Group 3: Future Plans and Vision - Baiyang Pharmaceutical aims to enhance the accessibility of high-quality medical resources and continue the development of the precision radiotherapy center, applying more advanced radiotherapy equipment in clinical settings [2] - The collaboration is seen as a stepping stone for future partnerships in critical areas, with a focus on building a leading medical model that prioritizes technology, service, and patient experience [1]

Core Viewpoint - The company has signed a cooperation agreement with Peking University International Hospital to jointly establish and operate a radiosurgery treatment center, focusing on innovative solutions for brain tumor patients [1] Group 1: Partnership Details - The cooperation agreement was signed on October 23, 2025, in Beijing [1] - The partnership aims to leverage resource complementarity and synergistic advantages to build a high-level radiotherapy platform [1] - The agreement outlines the rights and obligations of both parties in the collaboration [1] Group 2: Technological Focus - The center will utilize the ZAP-X Mars Rover radiosurgery robot operated by the company [1] - The focus will be on "specialized treatment for specialized diseases," particularly targeting brain tumors [1] - The initiative aims to optimize the precision radiotherapy scenarios for brain tumor patients, providing innovative treatment solutions for millions [1]

Core Insights - Baiyang Pharmaceutical has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center focused on brain tumors [1][3] - The ZAP-X device, operated by Baiyang, is designed to enhance the precision and safety of brain tumor radiotherapy, addressing the increasing incidence of brain metastases in China, which exceeds 1.5 million new cases annually [3] Group 1 - The collaboration aims to create a high-level radiotherapy platform that specializes in the treatment of brain tumors [1][3] - The ZAP-X device features an innovative dual-rotating spherical structure that allows X-rays to target tumors from thousands of non-coplanar angles, concentrating radiation on the tumor while minimizing exposure to surrounding healthy tissue [3] - ZAP-X has received regulatory approval in 24 countries and regions worldwide, with over 5,000 clinical treatments completed to date [3] Group 2 - Baiyang's chairman, Fu Gang, emphasized that this partnership is a significant step towards enhancing the clinical application of advanced radiotherapy equipment and improving access to quality medical resources [3]

Group 1 - The core viewpoint of the article is the strategic partnership between Baiyang Pharmaceutical and Peking University International Hospital to establish a precision radiotherapy center focused on brain tumor treatment [1] - The center will utilize the ZAP-X robotic radiosurgery system operated by Baiyang Pharmaceutical to enhance the precision of brain tumor radiotherapy [1] - The collaboration aims to create a specialized treatment platform for brain tumors, optimizing the radiotherapy experience [1]

Core Viewpoint - The company has signed a cooperation agreement with Peking University International Hospital to establish and operate a radiosurgery treatment center, enhancing the accessibility of quality medical resources [1] Group 1: Agreement Details - The cooperation agreement was signed on October 23, 2025, and has a duration of eight years from the date of signing [1] - The agreement includes clear provisions regarding termination and exit mechanisms, liability for breach, and dispute resolution [1] Group 2: Impact on Company - This collaboration is expected to improve the company's sustainable profitability and have a positive impact on its performance [1]

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号： | 2025-089 | | --- | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | | 二、交易合作方介绍 （一）基本情况 单位名称：北京大学国际医院 法定代表人：梁军 开办资金：15,000 万人民币 青岛百洋医药股份有限公司 关于签署合作协议的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次协议签署概况 为推动高端放疗设备临床落地、提高优质医疗资源可及性，发挥双方的资源 优势，青岛百洋医药股份有限公司（以下简称"公司""百洋医药"）与北京大学 国际医院（以下简称"北大国际医院"）于 2025 年 10 月 23 日在北京市签署了《放 射外科治疗中心合作协议》，约定双方通过资源互补、优势协同的方式开展合作， 共同建设并运营放射外科治疗中心，并对双方合作方式等权利义务作出明确约定。 本次签署协议审批权限在总经理权限范围内，公司已履行了签署本协议的内 部审批程序，无需公司董事会及股东会审议批准。 住所：北京市昌平区 ...

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.77% on October 17, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed mixed performance, with Jianfa Zhixin rising by 4.20% to a closing price of 28.05, while Baiyang Pharmaceutical fell by 3.09% to 25.75 [1][2] - Other notable performers included Yifeng Pharmacy (+1.19%), Dacilin (+1.10%), and Dajia Weikang (+0.35%) [1][2] Trading Volume and Value - Jianfa Zhixin had a trading volume of 194,100 shares and a transaction value of 547.1 million yuan, while Baiyang Pharmaceutical had a trading volume of 33,700 shares and a transaction value of 118.76 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 246 million yuan from institutional investors, while retail investors contributed a net inflow of 220 million yuan [2][3] - Notable capital flows included Jianfa Zhixin with a net inflow of 44.84 million yuan from institutional investors, while Baiyang Pharmaceutical experienced a net outflow of 964,800 yuan [3]

Group 1 - The 67th American Society for Radiation Oncology (ASTRO) annual meeting showcased ZAP Surgical's ZAP-X, a cutting-edge brain tumor precision radiotherapy robot, highlighting its technological breakthroughs and clinical results [1] - A peer-reviewed scientific study presented at the conference revealed significant differences in low-dose radiation spillover to healthy brain tissue across different platforms, with a maximum difference of up to 50 times [1] - ZAP-X demonstrated superior protection of healthy brain tissue compared to traditional radiotherapy devices, and it offers a 20% reduction in treatment time compared to specialized cranial radiotherapy equipment, enhancing treatment quality for patients with brain metastases [1] Group 2 - Despite advancements in stereotactic radiosurgery (SRS), nearly 80% of patients still lack access to high-quality treatment due to cost, facilities, and technical issues, particularly for benign and malignant brain tumors [2] - ZAP-X is designed to optimize brain precision radiotherapy using a pioneering dual-rotating spherical structure, achieving higher target doses while minimizing exposure to surrounding healthy tissue [2] - The system's innovations include sub-millimeter precision, real-time dose imaging, and ultra-low leakage from the collimator, setting a new benchmark in precision and safety for global radiosurgery [2] Group 3 - ZAP-X has received market approval in 24 countries and regions, with over 70 global clients and more than 5,000 clinical treatments completed [3] - The company is actively promoting the clinical implementation and global manufacturing of ZAP-X in China, with a high-end manufacturing base in Beijing set to become the global production supply center [3] - The company has established a comprehensive disease scenario layout in precision radiotherapy, covering brain, body, and cardiac treatments, and aims to drive the global deployment of top-tier radiotherapy technology through innovation and localized manufacturing [3]